Literature DB >> 10736279

Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability.

B Schieffer1, E Schieffer, D Hilfiker-Kleiner, A Hilfiker, P T Kovanen, M Kaartinen, J Nussberger, W Harringer, H Drexler.   

Abstract

BACKGROUND: Patients with an activated renin-angiotensin system (RAS) or genetic alterations of the RAS are at increased risk of myocardial infarction (MI). Administration of ACE inhibitors reduces the risk of MI, and acute coronary syndromes are associated with increased interleukin 6 (IL-6) serum levels. Accordingly, the present study evaluated the expression of angiotensin II (Ang II) in human coronary atherosclerotic plaques and its influence on IL-6 expression in patients with coronary artery disease. METHODS AND
RESULTS: Immunohistochemical colocalization of Ang II, ACE, Ang II type 1 (AT(1)) receptor, and IL-6 was examined in coronary arteries from patients with ischemic or dilated cardiomyopathy undergoing heart transplantation (n=12), in atherectomy samples from patients with unstable angina (culprit lesion; n=8), and in ruptured coronary arteries from patients who died of MI (n=13). Synthesis and release of IL-6 was investigated in smooth muscle cells and macrophages after Ang II stimulation. Colocalization of ACE, Ang II, AT(1) receptor, and IL-6 with CD68-positive macrophages was observed at the shoulder region of coronary atherosclerotic plaques and in atherectomy tissue of patients with unstable angina. Ang II was identified in close proximity to the presumed rupture site of human coronary arteries in acute MI. Ang II induced synthesis and release of IL-6 shortly after stimulation in vitro in macrophages and rat smooth muscle cells.
CONCLUSIONS: Ang II, AT(1) receptor, and ACE are expressed at strategic sites of human atherosclerotic coronary arteries, suggesting that Ang II is produced primarily by ACE within coronary plaques. The observation that Ang II induces IL-6 and their colocalization with the AT(1) receptor and ACE is consistent with the notion that the RAS may contribute to inflammatory processes within the vascular wall and to the development of acute coronary syndromes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736279     DOI: 10.1161/01.cir.101.12.1372

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  121 in total

1.  LDL cholesterol angiotensin II interactions in atherosclerosis.

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2001-05       Impact factor: 4.599

2.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

Review 3.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

4.  Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain.

Authors:  Chun Gu; Fang Wang; Zhihui Hou; Bin Lv; Yang Wang; Xiangfeng Cong; Xi Chen
Journal:  Heart Vessels       Date:  2017-07-19       Impact factor: 2.037

Review 5.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

6.  Cathepsin G activity lowers plasma LDL and reduces atherosclerosis.

Authors:  Jing Wang; Sara Sjöberg; Ting-Ting Tang; Katariina Oörni; Wenxue Wu; Conglin Liu; Blandine Secco; Viviane Tia; Galina K Sukhova; Cleverson Fernandes; Adam Lesner; Petri T Kovanen; Peter Libby; Xiang Cheng; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2014-08-01

Review 7.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

Review 8.  Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

Authors:  Milagros G Huerta; Jerry L Nadler
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

9.  Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD.

Authors:  Belinda Spoto; Francesco Mattace-Raso; Eric Sijbrands; Daniela Leonardis; Alessandra Testa; Anna Pisano; Patrizia Pizzini; Sebastiano Cutrupi; Rosa M Parlongo; Graziella D'Arrigo; Giovanni Tripepi; Francesca Mallamaci; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-09       Impact factor: 8.237

Review 10.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.